了解索拉费尼布诱导的铁和抵抗机制:对癌症治疗的影响
Qiuhong Li1, Kexin Chen1, Tianyi Zhang1
1School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan, China.
European journal of pharmacology
|July 17, 2023
概括
在肝癌治疗中,sorafenib会触发细胞死亡过程ferroptosis. 纳米药物正在开发中,以克服对这种疗法的耐药性并改善结果.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 细胞死亡机制 细胞死亡机制
背景情况:
- 索拉菲尼布是一种一线肝癌治疗,具有已知的安全性.
- 新型疗法可能会提供更好的疗效,但会带来安全性和成本方面的挑战.
- 索拉芬尼会诱导亡和铁亡,这是一种已知的免疫细胞死亡形式.
研究的目的:
- 审查索拉费尼布诱导的铁亡和耐药性的机制.
- 概述纳米医学战略,以克服铁灭性耐药性.
- 总结预测索拉费尼布耐药性的生物标志物.
主要方法:
- 关于Sorafenib机制,耐药性途径和纳米医学应用的文献综述.
- 对诱导铁亡和免疫细胞死亡的研究进行分析.
- 关于与索拉费尼布耐药性相关的分子生物标志物的数据汇编.
主要成果:
- 索拉费尼布的双重作用包括亡和铁亡诱导.
- 对索拉费尼布诱导的铁亡的耐药性是一个重大的临床挑战.
- 纳米药物通过克服耐药性来增强Sorafenib的疗效.
结论:
- 了解索拉费尼布诱导的铁和耐药性对于优化肝癌治疗至关重要.
- 纳米医学提供了创新的方法来增强Sorafenib的抗癌作用.
- 生物标志物识别可以指导Sorafenib治疗的个性化治疗策略.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.9K
08:02Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
5.7K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
